European Commission has approved bimekizumab (Bimzelx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis. Bimekizumab is a dual IL-17 inhibitor (IL-17A and IL-17F). https://t.co/viRNbx2cbt